Rigontec: Merck to Acquire Rigontec to Further ImmunoOncology Efforts
NewsMerck to acquire Rigontec RIGI therapeutics pioneer advancing leadership in immunooncology. Rigontecs proprietary agonists specifically activate theretinoic acidinducible gene I RIGI inducing both immediate and longterm antitumor immunity.
Read full article »
Rigontec develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases.
Read more